Ofloxacin microbiology: Difference between revisions

Jump to navigation Jump to search
mNo edit summary
mNo edit summary
Line 12: Line 12:
{|
{|
|-
|-
|[[File:OCUFLOX 2.jpg|thumb|1000px|left]]
|[[File:OCUFLOX 2.jpg|thumb|900px|left]]
|-
|-
|}
|}

Revision as of 23:32, 8 January 2014

Ofloxacin
OCUFLOX ® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

Microbiology

Ofloxacin has in vitro activity against a broad range of gram-positive and gram-negative aerobic and anaerobic bacteria. Ofloxacin is bactericidal at concentrations equal to or slightly greater than inhibitory concentrations. Ofloxacin is thought to exert a bactericidal effect on susceptible bacterial cells by inhibiting DNA gyrase, an essential bacterial enzyme which is a critical catalyst in the duplication, transcription, and repair of bacterial DNA.

Cross-resistance has been observed between ofloxacin and other fluoroquinolones. There is generally no cross-resistance between ofloxacin and other classes of antibacterial agents such as beta-lactams or aminoglycosides.

Ofloxacin has been shown to be active against most strains of the following organisms both in vitro and clinically, in conjunctival and/or corneal ulcer infections as described in the INDICATIONS AND USAGE section.

The safety and effectiveness of OCUFLOX® ophthalmic solution in treating ophthalmologic infections due to the following organisms have not been established in adequate and well-controlled clinical trials. OCUFLOX® ophthalmic solution has been shown to be active in vitro against most strains of these organisms but the clinical significance in ophthalmologic infections is unknown.

[1]

References

  1. "NOROXIN (NORFLOXACIN) TABLET, FILM COATED [MERCK SHARP & DOHME CORP.]". Retrieved 8 January 2014.

Adapted from the FDA Package Insert.